Cargando…

CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE

OBJECTIVE: Neurosurgery (NS) is an essential modality for large brain metastases (BM). As an adjuvant treatment, stereotactic radiosurgery (SRS) reduces neurocognitive toxicity without affecting post-treatment overall survival (OS) compared to whole brain radiation therapy. Pachymeningeal failure (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalyvas, Aristotelis, Gutierrez-Valencia, Enrique, Weiss, Jessica, O’ Halloran, Philip J, Mohan, Nilesh, Wong, Christine, Conrad, Tatiana, Millar, Barbara-Ann, Laperriere, Normand, Bernstein, Mark, Zadeh, Gelareh, Shultz, David, Kongkham, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354221/
http://dx.doi.org/10.1093/noajnl/vdac078.040
_version_ 1784763018075176960
author Kalyvas, Aristotelis
Gutierrez-Valencia, Enrique
Weiss, Jessica
O’ Halloran, Philip J
Mohan, Nilesh
Wong, Christine
Conrad, Tatiana
Millar, Barbara-Ann
Laperriere, Normand
Bernstein, Mark
Zadeh, Gelareh
Shultz, David
Kongkham, Paul
author_facet Kalyvas, Aristotelis
Gutierrez-Valencia, Enrique
Weiss, Jessica
O’ Halloran, Philip J
Mohan, Nilesh
Wong, Christine
Conrad, Tatiana
Millar, Barbara-Ann
Laperriere, Normand
Bernstein, Mark
Zadeh, Gelareh
Shultz, David
Kongkham, Paul
author_sort Kalyvas, Aristotelis
collection PubMed
description OBJECTIVE: Neurosurgery (NS) is an essential modality for large brain metastases (BM). As an adjuvant treatment, stereotactic radiosurgery (SRS) reduces neurocognitive toxicity without affecting post-treatment overall survival (OS) compared to whole brain radiation therapy. Pachymeningeal failure (PMF) beyond the SRS field is a relatively newly described entity, distinct from classical leptomeningeal failure (LMF), and unique to postoperative patients treated with adjuvant SRS. We sought to identify risk factors for PMF in patients treated with NS+SRS. METHODS: We reviewed a prospective registry (2009 to 2020) and identified all patients treated with NS+SRS. Clinical, radiological, pathological and treatment factors were analyzed. PMF incidence was evaluated using a competing risks model and differences between cohorts were measured using the Fine-Gray method. RESULTS: 144 Patients were identified. Median age was 62 (23-90). PMF occurred in 22.2% (32/144) patients). Univariate analysis indicated female gender (HR 2.65, p=0.013), higher GPA status (HR 2.4, p<0.001), absence of prior radiation therapy (HR N/A, p=0.018), controlled extracranial disease (CED) (HR 3.46, p=0.0038), and contact with the pia/dura (HR 3.30, p=0.0053) as risk factors for PMF. Piecemeal (vs En-bloc) resection also trended towards correlation (HR 2.07, p=0.054). Multivariate Analysis identified contact with pia/dura (HR 3.51, p=0.0053), piecemeal resection (HR 2.38, p=0.027), and CED (HR 3.97, p=0.0016) as significant correlates to PMF. PMF correlated with reduced OS (HR 2.90, p<0.001) but was improved compared to patients who developed LMF (HR 10.15, p= p<0.001). CONCLUSIONS: PMF is an underrecognized phenomenon that correlates with pre-operative pia/dura contact and piecemeal resection in patients treated with NS+SRS for BM. While less morbid than LMF, it is a critical event that deserves increased vigilance and analysis.
format Online
Article
Text
id pubmed-9354221
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93542212022-08-09 CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE Kalyvas, Aristotelis Gutierrez-Valencia, Enrique Weiss, Jessica O’ Halloran, Philip J Mohan, Nilesh Wong, Christine Conrad, Tatiana Millar, Barbara-Ann Laperriere, Normand Bernstein, Mark Zadeh, Gelareh Shultz, David Kongkham, Paul Neurooncol Adv Supplement Abstracts OBJECTIVE: Neurosurgery (NS) is an essential modality for large brain metastases (BM). As an adjuvant treatment, stereotactic radiosurgery (SRS) reduces neurocognitive toxicity without affecting post-treatment overall survival (OS) compared to whole brain radiation therapy. Pachymeningeal failure (PMF) beyond the SRS field is a relatively newly described entity, distinct from classical leptomeningeal failure (LMF), and unique to postoperative patients treated with adjuvant SRS. We sought to identify risk factors for PMF in patients treated with NS+SRS. METHODS: We reviewed a prospective registry (2009 to 2020) and identified all patients treated with NS+SRS. Clinical, radiological, pathological and treatment factors were analyzed. PMF incidence was evaluated using a competing risks model and differences between cohorts were measured using the Fine-Gray method. RESULTS: 144 Patients were identified. Median age was 62 (23-90). PMF occurred in 22.2% (32/144) patients). Univariate analysis indicated female gender (HR 2.65, p=0.013), higher GPA status (HR 2.4, p<0.001), absence of prior radiation therapy (HR N/A, p=0.018), controlled extracranial disease (CED) (HR 3.46, p=0.0038), and contact with the pia/dura (HR 3.30, p=0.0053) as risk factors for PMF. Piecemeal (vs En-bloc) resection also trended towards correlation (HR 2.07, p=0.054). Multivariate Analysis identified contact with pia/dura (HR 3.51, p=0.0053), piecemeal resection (HR 2.38, p=0.027), and CED (HR 3.97, p=0.0016) as significant correlates to PMF. PMF correlated with reduced OS (HR 2.90, p<0.001) but was improved compared to patients who developed LMF (HR 10.15, p= p<0.001). CONCLUSIONS: PMF is an underrecognized phenomenon that correlates with pre-operative pia/dura contact and piecemeal resection in patients treated with NS+SRS for BM. While less morbid than LMF, it is a critical event that deserves increased vigilance and analysis. Oxford University Press 2022-08-05 /pmc/articles/PMC9354221/ http://dx.doi.org/10.1093/noajnl/vdac078.040 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Kalyvas, Aristotelis
Gutierrez-Valencia, Enrique
Weiss, Jessica
O’ Halloran, Philip J
Mohan, Nilesh
Wong, Christine
Conrad, Tatiana
Millar, Barbara-Ann
Laperriere, Normand
Bernstein, Mark
Zadeh, Gelareh
Shultz, David
Kongkham, Paul
CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
title CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
title_full CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
title_fullStr CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
title_full_unstemmed CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
title_short CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
title_sort clrm-20 identifying risk factors and analyzing survival following pachymeningeal failure
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354221/
http://dx.doi.org/10.1093/noajnl/vdac078.040
work_keys_str_mv AT kalyvasaristotelis clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT gutierrezvalenciaenrique clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT weissjessica clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT ohalloranphilipj clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT mohannilesh clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT wongchristine clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT conradtatiana clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT millarbarbaraann clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT laperrierenormand clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT bernsteinmark clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT zadehgelareh clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT shultzdavid clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure
AT kongkhampaul clrm20identifyingriskfactorsandanalyzingsurvivalfollowingpachymeningealfailure